Association of Oral Antidiabetic Medications with Hypoglycemia in Type 2 Diabetic Patients Fasting during Ramadan
IAR Journal of Pharmacy · 24.06.2023 · 4 (1) · 1-6
DOI: 10.47310/iarjp.2023.v04i01.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift IAR Journal of Pharmacy, online erschienen am 24.06.2023. Verfasst von Sinan Ridha Khadem und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Skipping meals and a reduction in food intake besides the using of oral antidiabetic therapy are the main causes for developing hypoglycemia in T2DM patients who fast in Ramadan.
Aim
Comparing hypoglycemic events may be caused by different types of oral antidiabetic therapy in fasting diabetic patient’s type II and providing pharmaceutical care, patient education to improve glycemic control to decrease risk of hypoglycemia during Ramadan. Patients and Methods: This study is conducted on 211 T2DM, who were on one or more of the following oral antidiabetic therapy: Biguanides (Metformin), Sulphonylureas (Glibenclamide, Glimepiride), at the Diabetic Outpatient Clinic of Azadi Teaching Hospital in Kirkuk City during the 1st of June to 30th of September 2015 The face-to-face structured interview approach was used in the current study, based on standardized questionnaires before and during Ramadan. Outcome measures, such as HbA1c, serum total cholesterol, triglyceride fasting blood glucose level were collected before Ramadan and the response to the questionnaire were collected before and during Ramadan.
Results
Of 211 patients were included in the study, (n = 46 for metformin, n = 53 for glibenclamide, n=60 for glibenclamide plus metformin and n = 52 for glimepiride plus metformin) the proportion of patients who recorded symptomatic hypoglycemic events during Ramadan was zero% in the metformin group, 4% in glimepiride while 8.2% in glibenclamide group and 25% in glibenclamide plus metformin group (p<0.05). There were no reports of severe hypoglycaemia and no reports of patients requiring hospitalization or medical assistance due to hypoglycemia during the study.
Conclusions
Muslim patients with T2DM may fast safely in Ramadan by pre-Ramadan dose adjustment, patient education regarding self-monitoring and awareness of the risk of hypoglycemia. In this study metformin was not associated with hypoglycemia it found to be a safe antidiabetic therapy to be used in Ramadan, followed by the lower incidence of hypoglycemia with glimepiride plus metformin. Glibenclamide and glibenclamide plus metformin was found with high risk of hypoglycemia.
Zitieren
APA
Khadem, S. R., & Saeed, K. H. (2023). Association of Oral Antidiabetic Medications with Hypoglycemia in Type 2 Diabetic Patients Fasting during Ramadan. IAR Journal of Pharmacy, 4(1), 1-6. https://doi.org/10.47310/iarjp.2023.v04i01.006
Vancouver
Khadem SR, Saeed KH. Association of Oral Antidiabetic Medications with Hypoglycemia in Type 2 Diabetic Patients Fasting during Ramadan. IAR Journal of Pharmacy. 2023;4(1):1-6. doi:10.47310/iarjp.2023.v04i01.006
BibTeX
@article{Khadem2023,
author = {Khadem, Sinan Ridha and Saeed, K. Hiwa},
title = {Association of Oral Antidiabetic Medications with Hypoglycemia in Type 2 Diabetic Patients Fasting during Ramadan},
journal = {IAR Journal of Pharmacy},
year = {2023},
volume = {4},
number = {1},
pages = {1--6},
doi = {10.47310/iarjp.2023.v04i01.006}
}
EUVIMED